

NSL 06596

# Presynaptic M<sub>1</sub> muscarinic cholinergic receptors mediate inhibition of excitatory synaptic transmission in the hippocampus in vitro

Robert D. Sheridan and Bernd Sutor

*Physiologisches Institut, Universität München, Munich (F.R.G.)*

(Received 10 August 1989; Revised version received 16 September 1989; Accepted 18 September 1989)

**Key words:** Hippocampus; Muscarinic receptor, M<sub>1</sub> receptor; Presynaptic terminal; Carbachol; Pirenzepine; Muscarinic subtype

The effects of the cholinergic agonist, carbachol (CCh), were examined in the rat hippocampal slice preparation. Intracellular recordings from CA1 pyramidal neurones revealed that CCh (1–3  $\mu$ M) inhibited excitatory postsynaptic responses evoked by stimulation of the Schaffer collateral/commissural pathway while, at the same time, direct excitability was enhanced. Extracellularly, CCh produced a concentration-dependent reduction of the amplitude of the field excitatory postsynaptic potential (field EPSP) recorded in the CA1 apical dendritic region. The muscarinic receptor antagonist, pirenzepine, competitively antagonized the effects of CCh on the field EPSP with a  $pA_2$  of 7.4. These results confirm earlier reports of a presynaptic inhibitory action of CCh in the hippocampal CA1 region and provide strong evidence that this effect is mediated by muscarinic receptors of the M<sub>1</sub> subtype.

The classification of muscarinic receptors into two broad categories on the basis of their high (M<sub>1</sub>) and low (M<sub>2</sub>) affinities for the antagonist, pirenzepine [9], has prompted a number of attempts to establish the subtypes mediating the electrophysiological responses to muscarinic agonists throughout the brain [4–6, 14–16, 19]. In hippocampal CA1 pyramidal neurones, both the membrane depolarization and blockade of  $I_{AHP}$  induced by carbachol (CCh) have been attributed to an action at M<sub>1</sub> receptors, whereas inhibition of the M-current may result from M<sub>2</sub> receptor activation [4]. In addition to these postsynaptic effects, muscarinic agonists can also reduce the synaptically-evoked excitation of CA1 neurones by a presynaptic mechanism [11, 18]. Unfortunately, attempts to classify this latter response in terms of receptor subtype have yielded conflicting reports: both M<sub>2</sub> [4] and M<sub>1</sub> [16] receptors have been implicated. However, since neither of these earlier studies employed formal quantitative pharmacological procedures, conclusions from them must remain tentative. We

---

*Correspondence:* R.D. Sheridan, Physiologisches Institut, Universität München, Pettenkoferstraße 12, D-8000 Munich 2, F.R.G.




Fig. 1. Intracellular recordings from a single CA1 pyramidal neurone (RMP =  $-66$  mV). A: CCh ( $3 \mu\text{M}$ ) reversibly reduced the EPSC evoked by electrical stimulation of the SCC pathway (holding potential,  $V_h = -70$  mV). To facilitate comparisons of the EPSCs in the absence and presence of drug, the small inward current induced by CCh has been subtracted from the centre trace. B: effect of CCh ( $3 \mu\text{M}$ ) on spike trains generated by depolarizing current injection ( $0.15$  nA,  $300$  ms). During drug application, the membrane potential was manually clamped to  $-66$  mV to compensate for the small depolarization induced by CCh in this cell ( $5$  mV). Note the reversible enhancement by CCh of discharge frequency together with a reduction of the afterhyperpolarization. Records in B were obtained immediately after the corresponding voltage-clamp measurements shown in A.

have therefore re-examined the identity of the presynaptic muscarinic receptor underlying inhibition of excitatory transmission in CA1 using full Schild analysis [2] of the antagonistic effects of pirenzepine on the CCh-induced suppression of the field excitatory postsynaptic potential (EPSP).

Transverse slices of hippocampus (thickness  $500 \mu\text{m}$ ), prepared from adult male Sprague–Dawley rats, were stored in an artificial cerebrospinal fluid (CSF) containing (in mM): NaCl 124, KCl 5,  $\text{CaCl}_2$  2.5,  $\text{MgSO}_4$  2,  $\text{NaH}_2\text{PO}_4$  1.25,  $\text{NaHCO}_3$  22, D-glucose 10, gassed at room temperature with 95%  $\text{O}_2$ /5%  $\text{CO}_2$ . After at least 1 h, one slice was transferred to the recording chamber and submerged in continuously flowing artificial CSF at  $30$ – $33^\circ\text{C}$ . A concentric stimulation electrode, placed in the Schaffer collateral/commissural (SCC) pathway, was used to evoke synaptic excitation of neurones in area CA1 (stimulation frequency:  $0.05$  Hz). For the intracellular experiments glass electrodes containing  $4$  M potassium acetate (pH 7.2; resistance  $60$ – $90$   $\text{M}\Omega$ ) were used. Voltage-clamp measurements of excitatory postsynaptic currents (EPSCs) were made using a switched current- and voltage-clamp amplifier (npi SEC 1L, switching frequency  $18$ – $20$  kHz, 25% duty cycle) (see Ref. 17). To minimize contamination of EPSCs by inhibitory inputs, synaptic currents evoked by low stim-

ulation intensities were recorded at a holding potential ( $V_H$ ) corresponding to the reversal potential of the  $\gamma$ -aminobutyric acid A (GABA<sub>A</sub>)-mediated, chloride-dependent inhibitory postsynaptic current (IPSC;  $-67$  to  $-72$  mV) [1]. At this potential the amplitude of the IPSC should be negligible. A late, potassium-dependent IPSC was not observed at the low stimulation intensities used. For the extracellular experiments glass micropipettes containing 4 M NaCl (resistance 2–5 M $\Omega$ ) were used to record field EPSPs in the apical dendritic region of area CA1. Care was taken to adjust the stimulation current so that the field EPSPs were free from contaminating population spikes. Cumulative dose–response curves to CCh were constructed for each slice, allowing 15 min equilibration at each concentration. Following completion of the control dose–response curve, the slice was superfused with drug-free solution for 30 min. (Only slices in which the field EPSP amplitude returned to within  $\pm 5\%$  of the initial control value were included in subsequent antagonism studies.) The slice was then superfused with pirenzepine (0.1, 0.3 or 1  $\mu$ M) for 45 min, after which the dose–response curve to CCh was repeated. Only one antagonist concentration was applied to each slice. Concentration–response curves were fitted by non-linear regression (weighted by actual distance). Antagonism data were analysed by the method of Arunlakshana and Schild [2], dose-ratios being derived for each slice and then pooled. Grouped data are expressed as mean  $\pm$  S.E.M.

Firstly, the effects of CCh on the excitability of single CA1 neurones (resting membrane potential, RMP  $> -65$  mV, input resistance  $> 50$  M $\Omega$ ;  $n=4$ ) were investigated. In agreement with others, CCh (1–3  $\mu$ M) induced small membrane depolarizations (5–8 mV), increased input resistance (9–15%), blocked the adaptation of firing seen during prolonged depolarizing current injection and reduced the afterhyperpolarization associated with a spike train. In contrast, synaptically-driven responses were attenuated: both EPSPs and excitatory postsynaptic currents (EPSCs) evoked by low intensity stimulation of the SCC pathway were reversibly reduced. An example of the action of CCh on one cell is shown in Fig. 1.




Fig. 2. Concentration-dependent reduction of the extracellularly recorded field EPSP by CCh in a single slice in the absence (A) and presence (B) of pirenzepine (0.3  $\mu$ M). CCh concentrations ( $\mu$ M) are shown above the traces (averages of 3–5 sweeps). CCh was applied cumulatively (see text) and the records taken at 15 min following the start of each application. Arrows signify point of electrical stimulation.




Fig. 3. A: pooled concentration–response curves to CCh in the absence (●) and presence of 0.1 (◆), 0.3 (▲) and 1.0 μM (■) pirenzepine. Each curve was obtained from 3 to 12 slices (correlation coefficient  $r \geq 0.998$  in each case). B: Schild plot for the antagonism by pirenzepine of the effects of CCh on the field EPSP ( $r = 0.998$ ).

Superfusion of slices with CCh (0.1–3 μM) produced consistent, non-desensitizing reductions in the amplitude of the field EPSP: responses were stable after 10–12 min of drug application and readily reversible upon wash-out. A cumulative dosing schedule was therefore adopted in subsequent experiments, allowing 15 min at each concentration of CCh before progressing to the next. An example of the effect of CCh on the field EPSP from a single slice is shown in Fig. 2 and a summary from all slices studied is shown in Fig. 3A (control curve;  $EC_{50} = 1.43 \pm 0.15 \mu\text{M}$ ;  $n = 12$ ).

In the final series of experiments the antagonistic effects of pirenzepine on the CCh-induced depression of the field EPSP were studied. Pirenzepine (0.1, 0.3 or 1 μM) produced parallel rightward displacements of the CCh concentration–response curve (Fig. 3A). A Schild plot constructed from these data is shown in Fig. 3B ( $pA_2 = 7.38 \pm 0.06$ ; slope =  $1.03 \pm 0.04$ ).

In confirmation of earlier reports [11, 18], the present data provide evidence that CCh is able to depress excitatory synaptic transmission in the SCC/CA1 pathway by a presynaptic mechanism. Thus, although the direct excitability of CA1 neurones was enhanced by CCh, synaptically-evoked responses (EPSC and EPSP) were consistently depressed. That this latter action was mediated at a presynaptic locus is considerably strengthened by the fact that input resistance was invariably increased by CCh, an effect which would tend to potentiate synaptically-driven responses rather than diminish them. Extracellularly, CCh induced a concentration-dependent, pirenzepine-sensitive reduction of the amplitude of the field EPSP. The  $pA_2$  value of 7.38 for the antagonism by pirenzepine of this depressant action of CCh, is in close agreement with recent binding data for the interaction of pirenzepine with both cortical ( $pK_i = 7.7$ ; [7]) and hippocampal ( $pK_i = 7.43$ ; [3]) M<sub>1</sub> receptors labelled with [<sup>3</sup>H]pirenzepine.

That this presynaptic cholinergic mechanism may have some physiological relevance is supported by a recent report from Herreras et al. [10], who found that the potent inhibitory effect of sensory stimulation on SCC pathway-evoked CA1 field potentials in the anaesthetized rat was completely abolished by muscarinic, but not by GABAergic, antagonists. The morphological basis for a cholinergic innervation of the apical dendritic region of area CA1 is already firmly established [12].

In conclusion, our findings provide strong evidence that the presynaptic muscarinic receptor mediating depression of synaptic transmission in the SCC pathway is of the M<sub>1</sub> subtype. In this respect it is interesting that Williams and Constanti [19], using similar pharmacological techniques, have attributed the muscarinic depression of the synaptically-evoked potential in the olfactory cortex slice preparation also to an action at presynaptic M<sub>1</sub> receptors.

We are grateful to Prof. ten Bruggencate for helpful discussion. This work was supported by the Deutsche Forschungsgemeinschaft (SFB 220) and the Fraunhofer-Gesellschaft, München.

- 1 Alger, B.E. and Nicoll, R.A., Pharmacological evidence for two types of GABA receptor on rat hippocampal pyramidal cells studied in vitro, *J. Physiol. (Lond.)*, 328 (1982) 125–141.
- 2 Arunlakshana, O. and Schild, H.O., Some quantitative uses of drug antagonists, *Br. J. Pharmacol. Chemother.*, 14 (1959) 48–58.
- 3 Doods, H.N., Mathy, M.-J., Davidesko, D., van Charldorp, K.J., de Jonge, A. and van Zwieten, P.A., Selectivity of muscarinic antagonists in radioligand and in vivo experiments for the putative M<sub>1</sub>, M<sub>2</sub> and M<sub>3</sub> receptors, *J. Pharmacol. Exp. Ther.*, 242 (1987) 257–262.
- 4 Dutar, P. and Nicoll, R.A., Classification of muscarinic responses in hippocampus in terms of receptor subtypes and second-messenger systems: electrophysiological studies in vitro, *J. Neurosci.*, 8 (1988) 4214–4224.
- 5 Egan, T.M. and North, R.A., Acetylcholine acts on m<sub>2</sub>-muscarinic receptors to excite rat locus coeruleus neurons, *Br. J. Pharmacol.*, 85 (1985) 733–735.
- 6 Egan, T.M. and North, R.A., Acetylcholine hyperpolarizes central neurones by acting on an M<sub>2</sub> muscarinic receptor, *Nature (Lond.)*, 319 (1986) 405–407.
- 7 Eglen, R.M., Michel, A.D. and Whiting, R.L., Characterization of the muscarinic receptor subtype mediating contractions of the guinea-pig uterus, *Br. J. Pharmacol.*, 96 (1989) 497–499.
- 8 Halliwell, J.V. and Adams, P.R., Voltage-clamp analysis of muscarinic excitation in hippocampal neurons, *Brain Res.*, 250 (1982) 71–92.
- 9 Hammer, R., Berrie, C.P., Birdsall, N.J.M., Burgen, A.S.V. and Hulme, E.C., Pirenzepine distinguishes between different subclasses of muscarinic receptors, *Nature (Lond.)*, 283 (1980) 90–92.
- 10 Herreras, O., Solis, J.M., Herranz, A.S., Martin del Río, R. and Lerma, J., Sensory modulation of hippocampal transmission. II. Evidence for a cholinergic locus of inhibition in the Schaffer-CA1 synapse, *Brain Res.*, 461 (1988) 303–313.
- 11 Hounsgaard, J., Presynaptic inhibitory action of acetylcholine in area CA<sub>1</sub> of the hippocampus, *Exp. Neurol.*, 62 (1978) 787–797.
- 12 Houser, C.R., Crawford, G.D., Barber, R.P., Salvaterra, P.M. and Vaughn, J.E., Organization and morphological characteristics of cholinergic neurons: an immunocytochemical study with a monoclonal antibody to choline acetyltransferase, *Brain Res.*, 266 (1983) 97–119.
- 13 Madison, D.V., Lancaster, B. and Nicoll, R.A., Voltage clamp analysis of cholinergic action in the hippocampus, *J. Neurosci.*, 7 (1987) 733–741.
- 14 McCormick, D.A. and Prince, D.A., Two types of muscarinic responses to acetylcholine in mammalian cortical neurons, *Proc. Natl. Acad. Sci. U.S.A.*, 82 (1985) 6344–6348.

- 15 Müller, W. and Misgeld, U., Slow cholinergic excitation of guinea pig hippocampal neurons is mediated by two muscarinic receptor subtypes, *Neurosci. Lett.*, 67 (1986) 107–112.
- 16 Sheridan, R.D., Szabadi, E. and Bradshaw, C.M., Inhibition by carbachol of the synaptic excitation of hippocampal CA1 neurones: mediation by M<sub>1</sub> muscarinic receptors?, *Br. J. Pharmacol.*, 92 Suppl. (1987) 544P.
- 17 Sutor, B. and Hablitz, J.J., EPSPs in rat neocortical neurons in vitro. I. Electrophysiological evidence for two distinct EPSPs, *J. Neurophysiol.*, 61 (1989) 607–620.
- 18 Valentino, R.J. and Dingledine, R., Presynaptic inhibitory effect of acetylcholine in the hippocampus, *J. Neurosci.*, 1 (1981) 784–792.
- 19 Williams, S.H. and Constanti, A., A quantitative study of the effects of some muscarinic antagonists on the guinea-pig olfactory cortex slice, *Br. J. Pharmacol.*, 93 (1988) 855–862.